192 related articles for article (PubMed ID: 36048862)
21. Long-term medical management of uterine fibroids with ulipristal acetate.
Donnez J; Donnez O; Matule D; Ahrendt HJ; Hudecek R; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Loumaye E
Fertil Steril; 2016 Jan; 105(1):165-173.e4. PubMed ID: 26477496
[TBL] [Abstract][Full Text] [Related]
22. Influence of Ulipristal Acetate Therapy on Uterine Fibroid-Related Symptoms and on Uterine and Fibroid Volumes and Vascularity Indices Assessed by Ultrasound.
Baggio S; Pomini P; Galeone F; Presti F; Santi L; Raffaelli R; Franchi M
J Ultrasound Med; 2018 Sep; 37(9):2215-2223. PubMed ID: 29498074
[TBL] [Abstract][Full Text] [Related]
23. Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids.
Szydłowska I; Marciniak A; Nawrocka-Rutkowska J; Rył A; Starczewski A
Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012826
[No Abstract] [Full Text] [Related]
24. Pathologic Changes in Uterine Leiomyomas After Extended Treatment With Ulipristal Acetate.
Chang MC; Latta E
Int J Gynecol Pathol; 2020 Mar; 39(2):146-151. PubMed ID: 30702466
[TBL] [Abstract][Full Text] [Related]
25. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
26. Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids.
Morgante G; Centini G; Troìa L; Orvieto R; De Leo V
Reprod Biol Endocrinol; 2020 May; 18(1):50. PubMed ID: 32430027
[TBL] [Abstract][Full Text] [Related]
27. RISING STARS: Role of MED12 mutation in the pathogenesis of uterine fibroids.
Ishikawa H; Kobayashi T; Kaneko M; Saito Y; Shozu M; Koga K
J Mol Endocrinol; 2023 Nov; 71(4):. PubMed ID: 37668348
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.
Donnez J; Hudecek R; Donnez O; Matule D; Arhendt HJ; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Terrill P; Osterloh I; Loumaye E
Fertil Steril; 2015 Feb; 103(2):519-27.e3. PubMed ID: 25542821
[TBL] [Abstract][Full Text] [Related]
29. Progesterone receptor integrates the effects of mutated MED12 and altered DNA methylation to stimulate RANKL expression and stem cell proliferation in uterine leiomyoma.
Liu S; Yin P; Kujawa SA; Coon JS; Okeigwe I; Bulun SE
Oncogene; 2019 Apr; 38(15):2722-2735. PubMed ID: 30538295
[TBL] [Abstract][Full Text] [Related]
30. Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis.
Kalampokas T; Kamath M; Boutas I; Kalampokas E
Gynecol Endocrinol; 2016; 32(2):91-6. PubMed ID: 26572056
[TBL] [Abstract][Full Text] [Related]
31. Long-term treatment of uterine fibroids with ulipristal acetate ☆.
Donnez J; Vázquez F; Tomaszewski J; Nouri K; Bouchard P; Fauser BC; Barlow DH; Palacios S; Donnez O; Bestel E; Osterloh I; Loumaye E;
Fertil Steril; 2014 Jun; 101(6):1565-73.e1-18. PubMed ID: 24630081
[TBL] [Abstract][Full Text] [Related]
32. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
Woodhead N; Pounds R; Irani S; Pradhan P
J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
[TBL] [Abstract][Full Text] [Related]
33. The place of selective progesterone receptor modulators in myoma therapy.
Donnez J; Donnez O; Courtoy GE; Dolmans MM
Minerva Ginecol; 2016 Jun; 68(3):313-20. PubMed ID: 26930390
[TBL] [Abstract][Full Text] [Related]
34. Progesterone Signaling and Uterine Fibroid Pathogenesis; Molecular Mechanisms and Potential Therapeutics.
Ali M; Ciebiera M; Vafaei S; Alkhrait S; Chen HY; Chiang YF; Huang KC; Feduniw S; Hsia SM; Al-Hendy A
Cells; 2023 Apr; 12(8):. PubMed ID: 37190026
[TBL] [Abstract][Full Text] [Related]
35. EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.
Nair HB; Santhamma B; Dileep KV; Binkley P; Acosta K; Zhang KYJ; Schenken R; Nickisch K
Sci Rep; 2019 Nov; 9(1):17279. PubMed ID: 31754172
[TBL] [Abstract][Full Text] [Related]
36. Hormones and pathogenesis of uterine fibroids.
Reis FM; Bloise E; Ortiga-Carvalho TM
Best Pract Res Clin Obstet Gynaecol; 2016 Jul; 34():13-24. PubMed ID: 26725037
[TBL] [Abstract][Full Text] [Related]
37. [The molecular mechanisms and morphological manifestations of leiomyoma reduction induced by selective progesterone receptor modulators].
Demura TA; Revazova ZV; Kogan EA; Adamyan LV
Arkh Patol; 2017; 79(3):19-26. PubMed ID: 28631712
[TBL] [Abstract][Full Text] [Related]
38. Differences in fibroid vascularity after three months of pre-treatment with leuprolide acetate or ulipristal acetate: A pilot study.
Frijlingh M; De Milliano I; Hehenkamp WJK; Huirne JAF
Eur J Obstet Gynecol Reprod Biol; 2020 Feb; 245():186-192. PubMed ID: 31679806
[TBL] [Abstract][Full Text] [Related]
39. Esmya
Powell M; Dutta D
Womens Health (Lond); 2016 Nov; 12(6):544-548. PubMed ID: 29334010
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
